InvestorsHub Logo
Followers 6
Posts 2155
Boards Moderated 0
Alias Born 11/26/2014

Re: fabius post# 133

Wednesday, 01/15/2020 1:09:05 PM

Wednesday, January 15, 2020 1:09:05 PM

Post# of 169
Fabius- How were the studies incomplete? I think they did all the required testing. Its just that more studies were done on IV as they are going for abuse deterrent IV labeleing. I think they ran the requested tests for oral and nasal. Maybe they cut corners but I am not sure??? The oral and nasal results were not spectacular but mostly inline with ADF Oxy. I think where they fall short is when the panel is asked the question do the benefits of this approval outweigh the risks? I think the benefits are:

1. Superior IV ADF performance.
2. No food effect.

Risks:

1. Oral and Nasal ADF performance in line with ADF Oxy.

In looking at that, I don't think panel says benefits outweigh the risks as ADF Oxy is not a drug with a spectacular track record.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPCIF News